Article | Published:

Design and evaluation of glomerulus mesangium-targeted PEG-PLGA nanoparticles loaded with dexamethasone acetate

Abstract

Mesangial proliferative glomerulonephritis (MsPGN), one of the most common glomerulonephritis pathological types, often leads to end-stage renal disease over a prolonged period. But the current treatment of MsPGN is non-specific and causes serious side effects, thus novel therapeutics and targeting strategies are urgently demanded. By combining the advantages of PEG-PLGA nanoparticles and the size selection mechanism of renal glomerulus, we designed and developed a novel PEG-PLGA nanoparticle delivery system capable of delivering dexamethasone acetate (A-DEX) into glomerular mesangium. We determined that 90 nm was the optimum size to encapsulate A-DEX for glomerular mesangium targeting based on the size-selection mechanism of glomerulus. After intravenous administration in rats, 90 nm DiD-loaded NPs were found to accumulate to a greater extent in the kidney and kidney cortex compared with the free DiD solution. The 90 nm A-DEX NPs are also more stable at room temperature and showed a sustained release pattern. In rat glomerular mesangial cells (HBZY-1) in vitro, we found that the uptake of 90 nm A-DEX NPs was both temperature-dependent and energe-dependent, and they were mostly engulfed via clathrin-dependent endocytosis pathways. In summary, we have successfully developed a glomerular mesangium-targeted PEG-PLGA NPs, which is potential for the treatment of MsPGN.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Ethics declarations

Competing interests

The authors declare no competing interests.

References

  1. 1.

    Turner JE. Glomerulonephritis therapy: is there a role for green tea? Kidney Int. 2011;80:563–4.

  2. 2.

    Javaid B, Quigg RJ. Treatment of glomerulonephritis: will we ever have options other than steroids and cytotoxics? Kidney Int. 2005;67:1692–703.

  3. 3.

    Zuckerman JE, Davis ME. Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney Dis. 2013;20:500–7.

  4. 4.

    Lahdenkari AT, Lounatmaa K, Patrakka J, Holmberg C, Wartiovaara J, Kestilä M, et al. Podocytes are firmly attached to glomerular basement membrane in kidneys with heavy proteinuria. J Am Soc Nephrol. 2004;15:2611–8.

  5. 5.

    Zuckerman JE, Choi CH, Han H, Davis ME. Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane. Proc Natl Acad Sci USA. 2012;109:3137–42.

  6. 6.

    Shimizu H, Hori Y, Kaname S, Yamada K, Nishiyama N, Matsumoto S, et al. SiRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol. 2010;21:622–33.

  7. 7.

    Choi CH, Zuckerman JE, Webster P, Davis ME. Targeting kidney mesangium by nanoparticles of defined size. Proc Natl Acad Sci USA. 2011;108:6656–61.

  8. 8.

    Pollinger K, Hennig R, Bauer S, Breunig M, Tessmar J, Buschauer A, et al. Biodistribution of quantum dots in the kidney after intravenous injection. J Nanosci Nanotechnol. 2014;14:3313–9.

  9. 9.

    Campos IMF, Santos TM, Cunha GMF, Silva KMMN, Domingues RZ, Cunha AD, et al. Preparation and release characteristics of dexamethasone acetate loaded organochlorine-free poly (lactide-co-glycolide) nanoparticles. J Appl Polym Sci. 2014;131:41199.

  10. 10.

    Ameller T, Marsaud V, Legrand P, Gref R, Renoir JM. In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure antiestrogen. Int J Cancer. 2003;106:446–54.

  11. 11.

    Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32:8010–20.

  12. 12.

    Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, Yamchi MR, Milani M, Zarghami N, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15:517–35.

  13. 13.

    Li S, Zeng YC, Zhang ZR. Preparation and characterization of dexamethasone acetate loaded PEG-PLGA nanoparticles. West China J Pharm Sci. 2017;32:124–6.

  14. 14.

    Zhang T, Zheng Y, Peng Q, Cao X, Gong T, Zhang ZR. A novel submicron emulsion system loaded with vincristine–oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. Int J Nanomed. 2013;8:1185–96.

  15. 15.

    Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–15.

  16. 16.

    Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 2012;64:72–82.

  17. 17.

    Nabi IR, Le PU. Caveolae/raft-dependent endocytosis. J Cell Biol. 2003;161:673–7.

  18. 18.

    Mahmud A, Lavasanifar A. The effect of block copolymer structure on the internalization of polymeric micelles by human breast cancer cells. Colloids Surf B Biointerfaces. 2005;45:82–9.

  19. 19.

    Sun VZ, Li Z, Deming TJ, Kamei DT. Intracellular fates of cell-penetrating block copolypeptide vesicles. Biomacromolecules. 2011;12:10–3.

  20. 20.

    Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly (D, L-Lactide-co-Glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res. 2003;20:212–20.

  21. 21.

    Zuckerman JE, Gale A, Wu P, Ma R, Davis ME. SiRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther. 2015;25:53–64.

  22. 22.

    Langston Suen WL, Chau Y. Size-dependent internalisation of folate-decorated nanoparticles via the pathways of clathrin and caveolae-mediated endocytosis in ARPE-19 cells. J Pharm Pharmacol. 2014;66:564–73.

  23. 23.

    Qaddoumi MG, Ueda H, Yang J, Davda J, Labhasetwar V, Lee VHL. The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layers. Pharm Res. 2004;21:641–8.

  24. 24.

    Guo L, Luo S, Du ZW, Zhou ML, Li PW, Fu Y, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun. 2017;8:878.

  25. 25.

    Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly (DL-lactide-co- glycolide) nanoparticles: implications for drug and gene delivery. FASEB J. 2002;16:1217–26.

Download references

Acknowledgements

The work was supported by the National Natural Science Foundation of China (Nos. 81473169 and 81130060).

Author contributions

LZ and SL designed the research; SL, Y-cZ, KP, and CL performed the research; LZ and Z-rZ contributed new reagents or analytic tools; SL analyzed the data and wrote the draft manuscript; LZ contributed to manuscript writing and proofreading.

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Ling Zhang.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Keywords

  • Glomerulonephritis
  • Mesangium
  • Mesangial cells
  • PEG-PLGA nanoparticles
  • Dexamethasone acetate

Further reading

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9